10-K: vTv Therapeutics Announces Resumption of Phase 3 Trial After FDA Lifts Clinical Hold

vTv Therapeutics is set to resume its Phase 3 trial for cadisegliatin in Type 1 Diabetes after the FDA lifted a clinical hold, paving the way for further development of the potential adjunctive therapy.

Summary

• vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing oral treatments for metabolic and inflammatory diseases.
• The FDA lifted the clinical hold on cadisegliatin development program on March 14, 2025, and the company plans to resume its Phase 3 trial in the second quarter of 2025.
• The CATT1 trial will assess the effect of cadisegliatin on reducing the frequency of Level 2 and Level 3 hypoglycemia in 150 patients with T1D.
• A key secondary endpoint is the reduction in glycated hemoglobin (HbA1c) to assess the potential of cadisegliatin to reduce hyperglycemia.
• The company plans to amend the protocol of the CATT1 trial to remove the second 6-month period, which will allow them to obtain topline data from the trial sooner and expedite the start of the required pivotal trials.
• The FDA granted Breakthrough Therapy designation for cadisegliatin as an adjunctive therapy to insulin for the treatment of T1D in 2021.
• vTv Therapeutics is working with G42 Investments to initiate a Phase 2 trial in the Middle East for patients with T2D, expected to begin in 2025.
• The company is also seeking licensing deals for pipeline assets that are not currently partnered.
• In February 2024, the company closed a private placement, receiving approximately $51.0 million, and investors have the right to purchase up to an additional $30.0 million of Class A common stock on or before August 27, 2025.
• The company is working on the design and execution of two supportive trials in human volunteers to examine the effects of food on cadisegliatin's pharmacology and the potential effects of cadisegliatin on cardiac function (thorough QT study) as required by FDA guidance.
• The company will also start preparing plans for additional international registrational studies for cadisegliatin in T1D.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. The lifting of the clinical hold and planned resumption of the Phase 3 trial are positive developments. However, the company's financial situation, including accumulated losses and going concern uncertainty, tempers the overall outlook.

Positives

• FDA lifted the clinical hold on cadisegliatin, allowing the resumption of clinical trials.
• Breakthrough Therapy designation for cadisegliatin may expedite development and review timelines.
• Phase 2 SimpliciT-1 Study showed a clinically meaningful decrease (40%) in the frequency of severe and symptomatic hypoglycemia and in a statistically significant improvement in HbA1c relative to placebo.
• Private placement raised $51.0 million to advance cadisegliatin development.
• Planned Phase 2 trial in the Middle East with G42 Investments expands the potential application of cadisegliatin to T2D.

Negatives

• The company has incurred significant losses since inception and anticipates continued losses for the foreseeable future.
• There is substantial doubt as to the company's ability to continue as a going concern.
• The company has no products approved for commercial sale and has never generated any revenue from the commercialization of any product.
• The company will need additional capital to complete the development and commercialization of cadisegliatin and its other drug candidates.
• The company is dependent on limited sources of supply for the components used in cadisegliatin (TTP399) and its other drug candidates.

Risks

• The company's need for additional capital to continue the development and commercialization of its drug candidates.
• The potential failure of clinical trials or the inability to receive regulatory approval for drug candidates.
• The identification of serious adverse or unacceptable side effects which are determined to be drug-related.
• The company's ability to establish and maintain collaborative relationships to further the development of its drug candidates.
• The company's ability to continue to protect proprietary rights to its intellectual property.

Future Outlook

The company plans to resume the Phase 3 CATT1 trial in Q2 2025 and initiate a Phase 2 trial in the Middle East with G42 Investments in 2025. They are also seeking additional funding and strategic collaborations to support continued development.

Industry Context

The announcement comes amid increasing efforts to develop adjunctive therapies for Type 1 Diabetes, addressing the unmet need for improved glycemic control and reduced hypoglycemia risk. The lifting of the clinical hold allows vTv Therapeutics to re-enter the competitive landscape with its liver-selective glucokinase activator.

Comparison to Industry Standards

• The FDA's decision to lift the clinical hold on cadisegliatin is a positive sign, but the company still faces significant challenges in completing clinical trials and obtaining regulatory approval.
• Compared to companies like Biomea and TIXiMED, which are developing oral therapies for T1D, vTv Therapeutics is at a similar stage of development.
• However, companies like Vertex are further ahead with stem cell-based therapies.
• The company will need to demonstrate that cadisegliatin is safe and effective in order to compete with existing and emerging therapies.

Management Changes

Related Party Transactions

• The company has entered into several agreements with MacAndrews or its affiliates.
• The company is party to a tax receivable agreement with M&F, as successor in interest to vTv Therapeutics Holdings.
• The company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings.

Stakeholder Impact

• Shareholders: Potential for increased value if cadisegliatin is successful, but risk of dilution from future equity offerings.
• Employees: Job security and potential for career advancement if the company is successful.
• Patients: Potential for a new treatment option for Type 1 and Type 2 Diabetes.
• Collaborators: Opportunities for partnerships and revenue sharing.

Next Steps

• Resume Phase 3 CATT1 trial in Q2 2025.
• Design and execute supportive trials on food effects and cardiac function.
• Prepare plans for additional international registrational studies for cadisegliatin in T1D.
• Initiate Phase 2 trial in the Middle East with G42 Investments.
• Seek additional funding and strategic collaborations.

Key Dates

Keywords

cadisegliatin, TTP399, Type 1 Diabetes, T1D, clinical trial, FDA, glucokinase activator, GKA, hypoglycemia, G42 Investments, private placement, biopharmaceutical